Commission targets Lundbeck in antitrust probe
This article was originally published in SRA
Executive Summary
Lundbeck is the latest firm to become subject to investigation for alleged anticompetitive practices by the European Commission1. The commission says it is concerned that the company may be preventing generic citalopram from entering European Union markets.